Annexin Pharmaceuticals AB (OSTO:ANNX) EPS (Basic): kr-5.90 (TTM As of Mar. 2026)


OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr12.50
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB EPS (Basic)?

Annexin Pharmaceuticals AB OSTO:ANNX -1.19% 23 EPS (Basic) is kr-5.90 as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Annexin Pharmaceuticals AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr-1.47. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.90.

Annexin Pharmaceuticals AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-1.47. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-5.90.

Annexin Pharmaceuticals AB's EPS without NRI for the three months ended in Mar. 2026 was kr-1.47. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -5.90.

During the past 3 years, the average EPS without NRI Growth Rate was 28.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 20.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Annexin Pharmaceuticals AB's highest 3-Year average EPS without NRI Growth Rate was 43.50% per year. The lowest was -33.60% per year. And the median was 25.70% per year.

Annexin Pharmaceuticals AB  (OSTO:ANNX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Annexin Pharmaceuticals AB EPS (Basic) Related Terms

Annexin Pharmaceuticals AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB EPS (Basic) Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.89 -15.27 -23.40 -10.95 -5.50

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.46 -1.36 -1.51 -1.57 -1.47
OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Annexin Pharmaceuticals AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-36.893-0)/6.716
=-5.49

Annexin Pharmaceuticals AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-10.516-0)/7.166
=-1.47

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr-5.90 mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a EPS (Basic) of kr-5.90 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Annexin Pharmaceuticals AB and its competitors.
Is Annexin Pharmaceuticals AB's EPS (Basic) too high?
Annexin Pharmaceuticals AB's current EPS (Basic) is kr-5.90. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's EPS (Basic) compare to VRTX and REGN?
Annexin Pharmaceuticals AB's EPS (Basic) of kr-5.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current EPS (Basic) is kr-5.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current EPS (Basic) of kr-5.90. The current EPS (Basic) is kr-5.90. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current EPS (Basic) is kr-5.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.50
Price